Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research

News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971

Alexion Buys A Complementary Business With Achillion

Wed, 10/16/2019 - 1:05pm

The company agreed to pay $930m up front to acquire Achillion, which has two drugs in Phase II development for...

      Related Stories 

Galloping India Growth For Sacubitril/Valsartan Under Shadow Of Challenge

Wed, 10/16/2019 - 9:23am

Sacubitril/valsartan combination sales surge in India driving growth in the cardiac care segment even as Novartis and challenger Natco slug...

      Related Stories 

Roche Ups Outlook, Sees Spark Buy By Year-End

Wed, 10/16/2019 - 8:24am

Roche presented another strong quarterly performance and raised its outlook again for the full year, as sales continued to be...

      Related Stories 

Lilly Calls Time On UK Neuroscience Research Center

Wed, 10/16/2019 - 8:05am

The closure reflects the consolidation of neuroscience research in Cambridge, Mass, and Brexit is not to blame, says Lilly.

      Related Stories 

Ipsen Doubles Down On FOP With Blueprint Pact

Wed, 10/16/2019 - 7:36am

With the addition of BLU-782 to its soon-to-be filed fibrodysplasia ossificans progressiva drug palovarotene, Ipsen hopes to expand treatment options...

      Related Stories 

Shake It Off? Japan Mulls Routes Out Of Bioventure Doldrums

Tue, 10/15/2019 - 9:48pm

The long-recurring theme of how effectively to foster Japan’s bioventure sector again emerged as a key thread at recent major...

      Related Stories 

Reality Check? Granules Moves Out Of China JV

Tue, 10/15/2019 - 8:45pm

Indian firm Granules is exiting its long-standing joint venture for ibuprofen API in China against the backdrop of evolving pollution...

      Related Stories 

Asia Deal Watch: Daiichi Sankyo Acquires Partial Asian Rights To Three Astellas Drugs

Tue, 10/15/2019 - 12:30pm

Daichi Sankyo obtains right to antiemetic Nasea and the anti-hypertension drugs Perdipine and Oldeca. Mitsubishi Tanabe licenses Asian rights to...

      Related Stories 

Executives On The Move: Everest Poaches From Big Pharma; Gilead Gets New CMO

Tue, 10/15/2019 - 11:51am

China and Asia-focused Everest Medicines has poached a handful of senior hires from Sanofi, Abbott and Amgen, while Gilead Sciences’...

      Related Stories 

J&J's Tremfya Gets Its Blockbuster Wings

Tue, 10/15/2019 - 11:10am

The psoriasis drug was one of 10 J&J medicines that grew double digits in the third quarter, leading the company...

      Related Stories 

Reata Friedreich's Ataxia Drug Shows Late-Stage MOXIe

Tue, 10/15/2019 - 7:47am

Analysts have been surprised by positive pivotal data for omaveloxolone, one of Reata's Nrf2 activators – along with bardoxolone –...

      Related Stories 

Hilleman’s Shigella Vaccine Moves To Trials In Europe, Africa In ‘Big Step Forward’

Mon, 10/14/2019 - 7:07pm

India’s Hilleman Laboratories’ pioneering vaccine to treat shigellosis, a form of dysentery that’s a leading killer of young children, is...

      Related Stories 

Genentech Builds Case For Rituxan In Pemphigus With Comparator Study Data

Mon, 10/14/2019 - 1:52pm

Genentech reports that Rituxan yields better results over 52 weeks in pemphigus patients than off-label use of CellCept. Principia, meanwhile...

      Related Stories 

Payers Must Brace For Coming Wave Of Cell And Gene Therapies

Mon, 10/14/2019 - 1:38pm

One regenerative medicine for an ultra-rare disease may have a small impact, but payers will be flooded with dozens of...

      Related Stories